Form 4: United Therapeutics CEO Executes Pre-Planned Stock Sale

Chairperson and CEO Martine Rothblatt exercised 9,500 stock options and sold the resulting shares under a pre-arranged 10b5-1 trading plan.

Summary

• Martine Rothblatt, Chairperson and CEO of United Therapeutics, exercised 9,500 stock options at a strike price of $146.03.
• The acquired shares were immediately sold in a series of transactions on April 17, 2026.
• The sales were executed at weighted average prices ranging from approximately $575.38 to $592.30 per share.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on November 7, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; while it involves significant selling, the pre-planned nature of the 10b5-1 arrangement removes the signal of negative sentiment regarding company performance.

Positives

• The transaction was part of a pre-arranged 10b5-1 plan, indicating the sale was scheduled in advance rather than based on non-public information.
• The CEO maintains a significant remaining beneficial ownership stake in the company, including 40,513 shares held directly and substantial holdings across various family trusts.

Negatives

• The sale represents a liquidation of equity by the company's top executive, which can sometimes be perceived as a lack of long-term confidence, though this is mitigated by the pre-planned nature of the trade.

Risks

• The 10b5-1 plan is scheduled to continue until the earlier of December 31, 2026, or the exercise of 1,734,410 stock options, which may lead to continued selling pressure on the stock over the coming months.

Future Outlook

The reporting person intends to continue selling shares under the established 10b5-1 plan until the end of 2026 or until the specified 1,734,410 options are exhausted.

Management Comments

• The transactions were executed pursuant to a pre-arranged 10b5-1 trading plan adopted on November 7, 2025.

Industry Context

StockSavvy.ai notes that executive stock sales via 10b5-1 plans are standard practice in the biotech industry for liquidity and diversification, and this specific filing aligns with typical corporate governance expectations for a CEO of a major pharmaceutical firm.

Comparison to Industry Standards

• The use of 10b5-1 plans is the industry standard for executives to avoid allegations of insider trading.
• The volume of shares sold relative to the CEO's total holdings is consistent with typical executive compensation and diversification strategies seen at companies like Gilead Sciences or Amgen.

Related Party Transactions

• The filing discloses holdings in various family trusts where the reporting person or immediate family members are beneficiaries or trustees.

Stakeholder Impact

• Shareholders should note the ongoing scheduled liquidation of shares by the CEO, which may impact short-term supply and demand dynamics.

Next Steps

• Continued execution of the 10b5-1 trading plan through December 31, 2026.

Key Dates

Keywords

United Therapeutics, UTHR, Insider Trading, Martine Rothblatt, 10b5-1, Stock Options, Biotech